These data all revealed the key roles of ERG and MYCN in the propagation of CML cells with acquired imatinib resistance as SETD2 targets modulated by H3K36me3 alterations. The gene discussed is SETD2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.